We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




West Nile Serological Tests Assessed for Accuracy

By LabMedica International staff writers
Posted on 20 May 2013
West Nile virus (WNV) infections have increased incrementally with sporadic outbreaks in the last decade, and a variety of serological tests is used for the diagnosis. More...


Serological diagnosis of WNV infection can be performed by an enzyme-linked immunosorbent assay (ELISA), an immunofluorescence assay (IFA), a neutralization test (NT), and by the hemagglutination-inhibition assay.

Scientists at Robert Koch Institute (Berlin, Germany) working with a selected group of multinational laboratories organized the second external quality assurance (EQA) study for the serological diagnosis of WNV infection. The aim of this study was to collect updated information regarding the performance accuracy of WNV serological diagnostics.

A serum panel of 13 samples that included sera reactive against WNV, plus specificity and negative controls, was sent to 48 laboratories involved in WNV diagnostics. Forty-seven of 48 laboratories from 30 countries participated in the study. Only eight laboratories achieved 100% of concurrent and correct results. Of these eight tested panels, ELISA was performed in five, IFA in one and NT in two. In the other tested panels, the percentage of correct results varied from 54% to 92%.

No differences were observed in performances of in-house and commercial test used by the laboratories. IFA was significantly more specific compared to ELISA in detecting IgG antibodies. The overall analytical sensitivity was 50% and specificity was 95% for diagnostic tests for IgM detection. In comparison, the overall sensitivity was 86% and specificity was 69%, for diagnostic tests for IgG detection. The main obstacle in other laboratories to achieving similar performances was the cross-reactivity of antibodies amongst heterologous flaviviruses.

The authors concluded that there is still need to improve serological tests for WNV diagnosis. The low sensitivity of IgM detection suggests that there is a risk of overlooking WNV acute infections, whereas the low specificity for IgG detection demonstrates a high level of cross-reactivity with heterologous flaviviruses such as Dengue virus (DENV), Japanese encephalitis virus (JEV), Tick-borne encephalitis virus (TBEV), and Yellow fever virus. Due to the cross-reactivity with these flaviviruses, other diagnostic tests with heterologous flaviviruses should be performed to better identify false-positive results. The study was published on April 25, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Robert Koch Institute



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants

Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.